Agenus (NASDAQ:AGEN) issued its earnings results on Tuesday. The biotechnology company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.04), Fidelity Earnings reports. The company had revenue of $12.80 million during the quarter, compared to the consensus estimate of $10.76 million.

AGEN stock traded up $0.13 during trading on Wednesday, hitting $2.07. 2,337,152 shares of the company traded hands, compared to its average volume of 1,191,802. The stock has a market capitalization of $214.10 million, a PE ratio of -1.68 and a beta of 2.19. Agenus has a 1 year low of $1.54 and a 1 year high of $6.19.

Separately, Zacks Investment Research cut Agenus from a “hold” rating to a “sell” rating in a report on Monday, July 23rd.

A number of hedge funds have recently modified their holdings of the stock. Allianz Asset Management GmbH boosted its holdings in Agenus by 6.3% during the 1st quarter. Allianz Asset Management GmbH now owns 245,965 shares of the biotechnology company’s stock valued at $1,158,000 after acquiring an additional 14,634 shares during the period. A.R.T. Advisors LLC purchased a new stake in Agenus in the 1st quarter worth approximately $103,000. Schwab Charles Investment Management Inc. lifted its holdings in Agenus by 9.8% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 383,085 shares of the biotechnology company’s stock worth $870,000 after buying an additional 34,065 shares during the period. Northern Trust Corp lifted its holdings in Agenus by 4.0% in the 1st quarter. Northern Trust Corp now owns 964,199 shares of the biotechnology company’s stock worth $4,541,000 after buying an additional 37,027 shares during the period. Finally, Russell Investments Group Ltd. purchased a new stake in Agenus in the 1st quarter worth approximately $197,000. Institutional investors own 35.29% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This article was reported by Daily Political and is owned by of Daily Political. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this article can be accessed at https://www.dailypolitical.com/2018/11/07/agenus-agen-announces-quarterly-earnings-results-misses-expectations-by-0-04-eps.html.

Agenus Company Profile

Agenus Inc, a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies.

Recommended Story: What is a put option?

Earnings History for Agenus (NASDAQ:AGEN)

Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.